An exploratory, randomised, double-blind, placebo-controlled, 14-day, three-way crossover study, followed by an open label 1 day period when subjects will be dosed with intranasal fluticasone, nasal allergen challenge (NAC) study to evaluate the effects of SMP-028 on the release of inflammatory mediators after NAC with timothy grass pollen in subjects with allergic rhinitis out of season.

Trial Profile

An exploratory, randomised, double-blind, placebo-controlled, 14-day, three-way crossover study, followed by an open label 1 day period when subjects will be dosed with intranasal fluticasone, nasal allergen challenge (NAC) study to evaluate the effects of SMP-028 on the release of inflammatory mediators after NAC with timothy grass pollen in subjects with allergic rhinitis out of season.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Apr 2010

At a glance

  • Drugs SMP 028 (Primary)
  • Indications Allergic rhinitis
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
  • Acronyms NAC-SMP-028
  • Sponsors Dainippon Sumitomo Pharma
  • Most Recent Events

    • 01 Apr 2010 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials record.
    • 18 Nov 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top